Mechanistic Basis for Nonlinearities and Thresholds in Rat Liver Carcinogenesis by the DNA-Reactive Carcinogens 2-Acetylaminofluorene and Diethylnitrosamine
Free accessResearch articleFirst published online May, 2000
Mechanistic Basis for Nonlinearities and Thresholds in Rat Liver Carcinogenesis by the DNA-Reactive Carcinogens 2-Acetylaminofluorene and Diethylnitrosamine
To explore differences in mechanisms of carcinogenicity at low and high exposures, we have conducted a series of exposure-response studies of hepatocarcinogenesis in rats using 2 well-studied DNA-reactive carcinogens, 2-acetylaminofluorene and diethylnitrosamine. In these studies, we have used intraperitoneal injection or intragastric instillation to deliver exact doses during an initiation segment followed by phenobarbital as a liver tumor promoter to enhance manifestation of initiation. This protocol results in carcinogenicity comparable to that produced by lifetime exposure to the carcinogens. Our findings in these experiments provide evidence for the following: (a) formation of DNA adducts can be nonlinear, with a plateau at higher exposures; (b) cytotoxicity shows no-effect levels and is related to exposure; (c) compensatory hepatocyte proliferation shows no-effect levels and can be supralinear at high exposures; (d) formation of preneoplastic hepatocellular altered foci can show no-effect levels and appears supralinear at high exposures; (e) no-effect levels can exist for tumor development, and the exposure response can be supralinear. We interpret these findings to reflect thresholds for hepatocellular initiating effects of these carcinogens and exaggerated responses at high exposures attributable to cytotoxicity and compensatory hepatocyte proliferation. Such enhanced proliferation of hepatocytes harboring DNA damage likely results in an exaggerated yield of mutations in critical genes, leading to supralinear initiation of carcinogenesis. Thus, mechanisms differ between low and high exposures. Based on these observations, we suggest that linear extrapolation from high toxic exposures to postulated low-exposure effects of DNA-reactive carcinogens can yield overestimates. Such extrapolation must be supported by mechanistic information. The finding of no-effect levels provides a basis for understanding why low-level environmental exposures of humans to even DNA-reactive carcinogens may convey no cancer risk.
Chen B., Liu L., Castonguay A., Maronpot RR, Anderson MW, You ML ( 1993). Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone induced mouse lung tumors. Carcinogenesis14: 1603-1608.
2.
Cohen SM (1998). Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. Int J Toxicol17: 129-142.
3.
Counts JL, Goodman JI (1995). Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: Dose influences mechanism. Regul Toxicol Pharmacol21: 418-421.
4.
Den Otter W. , Koten JW, Van Der Vegt Bjh, Beemer FA, Boxma OJ, Derkinderen DJ, De Graaf PW, Hiber J., Lips Cjm, Roholl Pml, Sluijter Fjh, Tan Kewp, Van Der Heyden KA, Van Der Ven L., Van Unnik Jam (1990). Oncogenesis by mutations in anti-oncogenes: A view. Anticancer Res10: 475-488.
5.
Enzmann H., Zerban H., Kopp-Schneider A., Löser A., Bannasch P. (1995). Effects of low doses of N-nitrosomorpholine on the development of early stages of hepatocarcinogenesis. Carcinogenesis16: 1513-1518.
6.
Farmer JH, Kodell RL, Greenman DL (1979). Dose and time response models for the incidence of bladder and liver neoplasms in mice fed 2-acetylaminofluorene continuously . J Environ Pathol Toxicol3(3): 55-68.
7.
Frith CH, Farmer JH, Greenman DL, Saw GW ( 1979). Biologic and morphologic characteristics of urinary bladder neoplasms induced in BALB/c female mice with 2-acetylaminofluorene . In: Innovations in Cancer Risk Assessment (ED01 Study), Staffa JA, Mehlman MA (eds). Pathotox, Park Forest South, pp 103-119.
8.
Gebhardt R., Tanaka T., Williams GM (1989). Glutamine synthetase heterogeneous expression as a marker for the cellular lineage of preneoplastic and neoplastic liver populations. Carcinogenesis10: 1917-1923.
9.
Gebhardt R., Williams GM (1995). Glutamine synthetase and hepatocarcinogenesis . Carcinogenesis16: 2673-2681.
10.
Hard GC, Rodgers IS, Baetcke KP, Richards WL, McGaughy RE, Valcovic LR (1993). Hazard evaluation of chemicals that cause accumulation of α2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats. Environ Health Perspect99: 313-349.
11.
Hietanen E. , Husgafvel-Pursiainen K., Vainio H. (1997). Interaction between dose and susceptibility to environmental cancer: A short review. Environ Health Perspect105: 749-754.
12.
Hino O., Kitagawa T. (1981). Existence of a practical threshold dose for the hepatocarcinogen 3'-methyl-4-(dimethylamino)azobenzene in rat liver. Gann72: 637-638.
13.
Hirota N., Williams GM (1979). The sensitivity and heterogeneity of histochemical markers for altered foci involved in liver carcinogenesis. Am J Pathol95: 317-328.
14.
Hotchkiss J. (1989). Preformed N-nitroso compounds in foods and beverages. Cancer Surv8: 293-321.
15.
Hussain SP, Harris CC (1998). Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res58: 4023-4037.
16.
International Expert Panel on Carcinogen Risk Assessment (1996). The use of mechanistic data in risk assessments of ten chemicals: An introduction to the chemical-specific reviews. Pharmacol Ther71: 1-5.
17.
Lin J., Chen J., Elenbaas B., Levine AJ (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev8: 1235-1246.
18.
Loeb LA (1998). Cancer cells exhibit a mutator phenotype. Cancer Res72: 25-56.
19.
Manam S., Shinder GA, Joslyn DJ, Kraynak AR, Hammermeister CL, Leander KR, Ledwith DJ, Prahalada S., van Zwieten MJ, Nichols WW (1995). Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors. Carcinogenesis16: 1113-1119.
20.
Miller JA (1994). Sulfonation in chemical carcinogenesis-history and present status. Chem Biol Interact92: 329-341.
21.
National Research Council ( 1977). Safe Drinking Water and Health. National Academy of Sciences, Washington, DC.
22.
Nestmann ER , Bryant DW, Carr J., Fennell TT, Gallagher JE, Gorelick NJ, Swenberg JA, Williams GM (1996). Toxicological significance of DNA adducts. Report of an expert panel . Regul Toxicol Pharmacol140: 254-263.
23.
Neumann H-G. (1986). The role of DNA damage in chemical carcinogenesis of aromatic amines. J Cancer Res Clin Oncol112: 100-106.
24.
Österdahl B-G. (1991). Occurrence of an exposure to N-nitrosamines in Sweden: A Review. In: Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins, O'Neill IK, Chen JS, Bartsch H (eds). IARC Scientific Publication No 105, IARC, Lyon, France, pp 235-237.
25.
Page NP, Singh DV, Farland W., Goodman JI, Conolly RB, Anderson ME, Clewell HJ, Frederick CB, Yamasaki H., Lucier G. (1997). Implementation of EPA revised cancer assessment guidelines: Incorporation of mechanistic and pharmacokinetic data. Fundam Appl Toxicol37: 16-36.
26.
Peto R., Gray R., Branton P., Grasso P. (1991). Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. Cancer Res51: 6452-6469.
27.
Peto R., Gray R., Branton P., Grasso P. (1991). Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: A detailed dose-response study. Cancer Res51: 6415-6451.
28.
Ringer PR, Norton TR (1987). Further characterization of the ability of hepatocarcinogens to lower rat liver arylsulfotransferase activity. Carcinogenesis8: 1749-1752.
29.
Risk Assessment Forum ( 1991 ). Alpha2u-Globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the Male Rat. US Environmental Protection Agency, Washington, DC.
30.
Root M., Lange T., Campbell TC (1997). Dissimilarity in aflatoxin dose-response relationships between DNA adduct formation and development of preneoplastic foci in rat liver. Chem Biol Interact106: 213-227.
31.
Sen NP (1991). Recent studies in Canada on the occurrence and formation of N-nitroso compounds in foods and food contact materials. In: Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins, O'Neill IK, Chen JS, Bartsch H (eds). IARC Scientific Publication No 105, IARC. Lyon, France, pp 232-234.
32.
Swenberg JA , La DK, Scheller NA, Wu K-Y. (1995). Dose-response relationships for carcinogens. Toxicol Lett82/83: 751-756.
33.
Tong C., Fazio M., Williams GM (1980). Cell cycle-specific mutagenesis at the hypoxanthine phosphoribosyl-transferase locus in adult rat liver epithelial cells. Proc Natl Acad Sci USA77: 7377-7379.
34.
Umemura T., Tokumo K., Sirma H., Gebhardt R., Poirier MC, Williams GM (1993). Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Lett73: 1-10.
35.
Verna L., Whysner J., Williams GM (1996). 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation . Pharmacol Ther71: 83-106.
36.
Verna L., Whysner J., Williams GM (1996). N-nitrosodiethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation . Pharmacol Ther71: 57-82.
37.
Vineis P., Pirastu R. (1997). Aromatic amines and cancer. Cancer Causes Control8: 346-355.
38.
Wakabayashi K., Totsuka Y., Fukutome K., Oguri A., Ushiyama H., Sugimura T. (1997). Human exposure to mutagenic/carcinogenic heterocyclic amines and comutagenic beta-carbolines. Mutat Res376: 253-259.
39.
Watanabe L. , Williams GM (1978). Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital: Evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. J Natl Cancer Inst61: 1311-1314.
40.
Wei S-JC , Chang RL, Bhachech N., Cui XX, Merkler KA, Wong C-Q., Henning W., Yagi H., Jerina DM, Conney AH (1996). Dose-dependent differences in the profile of mutations induced by (+)-7R, 8S-dihydroxy-9S, 10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in Chinese hamster V-79 cells. Cancer Res53: 3294-3301.
41.
Wei S-JC , Chang RL, Cui XX, Merkler KA, Wong C-Q., Yagi H., Jerina DM, Conney AH (1996). Dose-dependent differences in the mutational profiles of (—)-1R,2S,3S,4R)-3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene and its less carcinogenic enantiomer. Cancer Res56: 3695-3703.
42.
Whysner J., Williams GM (1996). Butylated hydroxyanisole mechanistic data and risk assessment: Conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol Ther71: 137-152.
43.
Whysner J., Williams GM (1996). d-Limonene mechanistic data and risk assessment: Absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol Ther71: 127-136.
44.
Williams GM (1980). The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochem Biophys Acta605: 167-189.
45.
Williams GM (1997). Chemicals with carcinogenic activity in the rodent liver: Mechanistic evaluation of human risk. Cancer Lett118: 1-14.
46.
Williams GM (1999). Mechanistic considerations in cancer risk assessment. Inhalation Toxicology11: 549-554.
47.
Williams GM , Gebhardt R., Sirma H., Stenbäck F. (1993). Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine. Carcinogenesis14: 2149-2156.
48.
Williams GM , Iatropoulos MJ, Jeffrey AM, Luo F-Q., Wang C-X. (1999). Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation and initiation of carcinogenesis in rat liver display non-linearities and thresholds. Arch Toxicol73: 394-402.
49.
Williams GM , Iatropoulos MJ, Wang CX, Ali N., Rivenson A., Peterson LA, Schulz C., Gebhardt R. (1996). Diethylnitrosamine exposure-responses for DNA damage, centrilobular cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit some non-linearities . Carcinogenesis17: 2253-2258.
50.
Williams GM , Iatropoulos MJ, Wang C-X., Jeffrey AM, Thompson S., Pittman B., Palasch M., Gebhardt R. (1998). Non-linearities in 2-acetylaminofluorene exposure-responses for genotoxic and epigenetic effects leading to initiation of carcinogenesis in rat liver . Toxicol Sci45: 152-161.
51.
Williams GM , Reiss B., Weisburger JH (1985). A comparison of the animal and human carcinogenicity of several environmental, occupational and therapeutic chemicals. In: Mechanisms and Toxicity of Chemical Carcinogens and Mutagens. Advances in Environmental Toxicology, Flamm G, Lorentzen R (eds). Princeton Scientific Publishers, Princeton, New Jersey , pp 207-248.
52.
Williams GM , Tanaka T., Maruyama H., Maeura Y., Weisburger JH, Zang E. (1991). Modulation by butylated hydroxytoluene of liver and bladder carcinogenesis induced by chronic low level exposure to 2-acetylaminofluorene. Cancer Res51: 6224-6230.
53.
Williams GM , Watanabe K. (1978). Quantitative kinetics of development of N-2-fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion of persistence following removal of carcinogen. J Natl Cancer Inst61: 113-121.
54.
Williams GM , Whysner J. (1995). Mechanistic considerations in risk assessment for epigenetic tumor-promoting carcinogens. In: Growth Factors and Tumor Promotion: Implications for Risk Assessment, McClain RM, Slaga TJ, LeBoeuf R, Pitot H (eds). Wiley, New York , pp 369-383.
55.
Williams GM , Whynser J. (1996). Epigenetic carcinogens: Evaluation and risk assessment. Exp Toxicol Pathol48: 189-195.
56.
Williams JR , Russell J., Dicello JF, Mabry MH (1996). The genotype of the human cancer cell: Implication for risk analysis. Mutat Res365: 17-42.
57.
Wiltse J., Dellarco VL (1996). U.S. Environmental Protection Agency guidelines for carcinogen risk assessment: Past and future. Mutat Res365: 3-15.
